REG - Haleon PLC - Proposed purchase alongside Pfizer offering

HALEONAnnouncement

30/09/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240930:nRSd3182Ga&default-theme=true

RNS Number : 3182G  Haleon PLC  30 September 2024

 

Haleon plc: Proposed off-market purchase alongside Pfizer Inc. offering

 

30 September 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN)
notes the announcement today by Pfizer Inc. ("Pfizer") of its proposed
offering of ordinary shares of £0.01 each in the Company to institutional
investors by way of an accelerated bookbuild offering process (the "Proposed
Offering").

 

Haleon has agreed with Pfizer to make an off-market purchase of approximately
£230 million worth of ordinary shares from Pfizer, subject to completion of
the Proposed Offering. The purchase price per ordinary share to be paid by
Haleon in the off-market purchase will be equal to the offering price per
ordinary share in the Proposed Offering.

 

The off-market purchase includes approximately £114.6 million worth of
ordinary shares, which represents the remainder of the £500 million allocated
to share buybacks in 2024 announced on 29 February 2024. Haleon intends to
cancel these ordinary shares and end its on-market share buyback programme
launched on 1 August 2024.

 

Separate to the remaining capital allocated to buybacks in 2024, the
off-market purchase includes approximately £115.4 million worth of ordinary
shares that will be held as treasury shares for the purposes of satisfying
Haleon's obligations under its existing employee share plans in 2025.

 

Further details will be provided following announcement by Pfizer of the
results of the Proposed Offering.

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                    Media

 Sonya Ghobrial          +44 7392 784784      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Gemma Thomas        +44 7985 175048
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com)

 

 

Not for release, publication or distribution in the United States, Canada,
Japan, Australia or any other state or jurisdiction in which such release,
publication or distribution would be unlawful.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSDSFMSELSESU